# Empagliflozin + Linagliptin

## Glyxambi 25/5mg

##### 

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | OGXB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 適應症     | Type 2 diabetes mellitus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 用法用量   | Initial empagliflozin 10 mg/linagliptin 5 mg orally once daily in the morning, may increase to empagliflozin 25 mg/linagliptin 5 mg once daily if tolerated.                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 腎功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 禁忌       | Severe renal impairment, dialysis, or end-stage renal disease. Hypersensitivity reaction to empagliflozin, linagliptin, or any of the excipients; anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred.                                                                                                                                                                                                                                                                                                                                       |
| 副作用     | Common Renal: Urinary tract infectious disease (11.4% to 12.5% ) Respiratory: Nasopharyngitis (5.9% to 6.6% ), Upper respiratory infection (7% ) Serious Cardiovascular: Heart failure, Hypotension Endocrine metabolic: Diabetic ketoacidosis, Hypoglycemia (2.2% to 3.6% ) Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Musculoskeletal: Arthralgia Renal: Creatinine clearance-glomerular filtration abnormal, Decreased, Pyelonephritis, Sepsis due to urinary tract infection, Serum creatinine raised Reproductive: Necrotizing fasciitis, Perineum Other: Angioedema |
| 孕期建議   | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 哺乳期建議 | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

